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There has been a high incidence of tumor recurrence after 
liver transplantation for primary hepatic malignancy. Nev-
ertheless, a small but significant palliation has been possi-
ble with this approach, even in patients who eventually died 
of recurrence. Two patients with incidental malignancies in 
their excised livers apparently have been cured. Further 
gains will be possible only with extremely discriminating 
selection of prospective recipients. 
When orthotopic liver transplantation was first 
done on a human in 1963, it was thought that 
primary liver malignancy which could not be treat-
ed with conventional techniques of subtotal liver 
resection would be an unequivocal indication for 
total hepatectomy and liver replacement (orthotop-
ic liver transplantation) [1]. However, the high 
recurrence rate of the original liver malignancies 
partly invalidated this expectation [1-3]. A recent 
review of our 24 orthotopic liver transplantations 
performed in the presence of primary liver malig-
nancy has provided a more definitive idea of what 
can be achieved with this approach. 
Case Material 
During the 18-year period from March, 1963 to 
September, 1980, a total of 184 patients underwent 
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orthotopic liver transplantation. Twenty-four of the 
recipients had transplantation in the presence of a 
primary liver malignancy, and they were divided 
into 3 groups for analysis. Group I consisted of 3 
patients who had liver replacement for what was 
thought to be end-stage non-neoplastic liver dis-
ease, but who were found to have an incidental 
primary liver malignancy. Group II consisted of 8 
patients who received liver replacement because of 
primary liver malignancy, but who died within 30 
days from early postoperative complications. 
Group III consisted of 13 patients who received 
liver replacement because of liver malignancy and 
who survived more than 2 months. In this group, it 
was possible to make meaningful observations 
about tumor recurrence. 
Age, sex, diagnosis, survival, tumor recurrence, 
and main causes of death of all 3 groups of patients 
are listed in Tables 1, 2, and 3. The patients' ages 
ranged from 19 months to 68 years (mean, 31 years). 
There were 12 males and 12 females. Fifteen of the 
24 patients had hepatoma, 5 had carcinoma of 
intrahepatic bile ducts (Klatskin-type tumor), and 
one each had cholangiocarcinoma, hepatoblastoma, 
hemangioendothelial sarcoma, and sarcoma of un-
determined cell type. 
Results 
Group I 
Two (OT 33, OT 142) of the 3 recipients who had 
concomitant incidental primary liver malignancy 
are still alive and well without any evidence of 
-- ----- ---
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Table 1. Fate of 3 patients who received liver replacement primarily for end-stage benign liver disease, but who were found to have 
primary liver malignancy as well (Group I). 
Patient/age 
(yr)/sex 
OT 33 3/F 
OT 80 7/F 
OT 142 5/F 
Primary indication for 
transplant 
Biliary atresia 
Biliary atresia 
Alpha-I antitrypsin deficiency 
Incidentally found 
liver malignancy 
Hepatoma 
Hepatoma 
Hepatoblastoma 
Survival 
Alive more than II years 
Postoperative death 
Alive at 3 years 
Tumor 
recurrence 
No 
No 
Main cause 
of death 
Cardiac arrest 
Table 2. Fate of 8 patients who received liver replacement for indication of primary liver malignancy, but did not survive long enough 
after operation to permit observation of the course of the malignancy (Group 10. 
---- - - .- ----
----------- ----------- ----
Patient/age (yr)/sex 
OT 2 48/M 
OT 3 68/M 
OT 4 52/M 
OT 5 29/F 
OT 6 29/M 
OT 7 24/F 
OT 25 45/M 
OT 79 60/M 
Diagnosis 
Hepatoma and cirrhosis 
Adenocarcinoma of bile duct 
(Klatskin tumor) 
Cholangiocarcinoma 
Hepatoma 
Hepatoma 
Hepatoma 
Hepatoma 
Carcinoma of bile duct 
(Klatskin tumor) 
Survival 
21 days 
8 days 
5 days 
24 days 
7 days 
17 days 
29 days 
19 days 
Metastases at autopsy 
and location 
No 
No 
Bone, lung, kidney, 
lymph nodes 
No 
No 
No 
No 
No 
Main cause of death 
Pulmonary emboli, sepsis 
Sepsis, pulmonary emboli, gastro-
intestinal bleeding 
Pulmonary emboli, hepatic failure, 
pulmonary edema 
Sepsis, bile peritonitis, hepatic 
failure 
Hepatic failure, sepsis 
Pneumonitis 
Bile peritonitis, sepsis, hepatic 
failure 
Hepatic failure due to biliary 
obstruction 
----- ----------------- ----- --------
Table 3. Fate of 13 patients who received liver replacement for indication of primary liver malignancy and who lived long enough to 
---------
Patient/age Recurrence Metastases of 
(yr)/sex Diagnosis first detected Location of first recurrence homograft 
- ------- --- -----
OT 8 P/dF Hepatoma 3 mos Lungs Yes 
OT 14 16/F Hepatoma 13 mos Diaphragm. liver, retroperitoneal space Yes 
OTIS 43/M Hepatoma. cirrhosis 2 mos LUngs Yes 
OT23 151M Hepatoma I mos Lungs Yes 
OT 26 II/F Biliary atresia, hepatoma 3 mos Lungs No 
OT 45 53/M Hemangioendothelial sarcoma 2V, mos Lungs, liver Yes 
OT 78 48/M Adenocarcinoma of bile duct 
(Klatskin tumor) 21 mos Liver, bile duct Yes 
OT 90 4I1M Cholangiocarcinoma of bile duct 
(Klatskin tumor) 42 mos Bile duct Yes 
OT 102 51/P Cholangiocarcinoma of bile duct 
(Klatskin tumor) No No No 
OT III 9/F Congenital tyrosinemia, hepatoma, 
cirrhosis No No No 
OT 114 27/F Sarcoma (undetermined cell type) of liv- Residual tumor No 
er invading diaphragm, metastasis to at transplant 
right lung and peritoneum 
OT 121 32/F Hepatoma No No No 
OT I72 241M Hepatoma No No No 
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tumor recurrence, one (OT 142) after 3 years and 
the other (OT 33) after more than 11 years. The 
third patient (OT 80) died from cardiac arrest just 
after the transplant operation; careful postmortem 
search for residual tumor failed to show any spread 
of tumor outside the liver (Table 1). 
Group II 
These 8 patients (liver replacement for known pri-
mary liver malignancy but with death during the 
first 30 postoperative days) were not suitable for 
assessment of tumor recurrence, but their postmor-
tem examinations were used to determine residual 
tumor unknowingly left after total hepatectomy. 
Preoperatively, all 8 were thought to be free of 
extrahepatic tumors. At autopsy, only 1 patient 
(OT4) had residual neoplasm. This patient survived 
only 5 days after liver replacement and the postmor-
tem examination revealed cholangiocarcinoma in 
the lung, vertebra, kidney, and some abdominal 
lymph nodes. The remaining 7 patients were tumor-
free insofar as this could be determined from com-
plete postmortem examination (Table 2). Thus, 
screening for candidacy had been grossly accurate 
in 87.5% of the cases with only 1 error out of 8 
cases. 
permit observations about the course of the malignancy (Group llI). 
Treatment of recurrent tumor Organs ultimately involved 
83 
Group III 
Thirteen patients had liver replacement for known 
primary liver malignancy and survived after trans-
plantation for more than 2 months. Ten patients had 
recurrence of the original tumor and 7 of them died 
of the malignancy (Table 3). An eighth patient 
developed a single pulmonary metastasis, but her 
death after 3 months was from infection and gastro-
intestinal hemorrhage. A ninth patient who original-
ly had congenital tyrosinemia and hepatoma died of 
portal vein thrombosis after 3 months. She had 
metastases in the lung and abdominal lymph nodes. 
The tenth patient represented an extraordinary ex-
ample of tumor quiescence or even involution. The 
primary liver tumor was removed at transplanta-
tion, but there were fine miliary metastases on the 
pleura and peritoneum. She is still well after more 
than 4 years. The tumor was examined by patholo-
gists at the University of Colorado, St. Mary's 
Hospital and Medical School (London), the Armed 
Forces Institute of Pathology (District of Colum-
bia), and the University of Southern California. All 
agreed that the tumor was malignant and the major-
ity opinion was sarcoma of unknown subclassifica-
tion. Minority opinions were sclerosing cholangio-
carcinoma, sclerosing angiosarcoma, and mixed 
tumor of the liver. 
Time of 
death Main causes of death 
----------------------- ----------------_ .. _------
Chemotherapy, radiation, debulking 
of abdominal mass 
Radiation 
Brains, lungs, liver. other abdominal 
organs 
Diaphragm. retroperitoneal space, 
liver, pancreas 
Lungs, liver, diaphragm 
Brain, lungs, liver. retroperitoneal 
space 
Lung 
Brain, lungs, liver, spleen, pericardi-
14 mos 
15 mos 
12 mos 
5 mas 
3 mos 
um, peritoneum, stomach, pancreas, 3 mas 
kidney 
Liver, bile duct at reoperation. No 
autopsy 25 mos 
Bile duct, liver, duodenum at reopera- 54 mas 
tion. No autopsy 
None 3 mos 
Microscopic metastasis in the lung and 3 mas 
para-aortic lymph nodes at autopsy 
Grossly fine intra-abdominal and pul-
monary metastases at operation Alive 52 
which have been quiescent greater mas 
than 4 years 
None 
None 
6 mos 
Alive 10 
mos 
Carcinomatosis 
Carcinomatosis: infection and duode-
nal fistula after retransplantation 
Carcinomatosis 
Carcinomatosis 
Gastrointestinal hemorrhage, intra-
abdominal sepsis 
Sarcomatosis 
Tumor recurrence 
Tumor recurrence 
Systemic candidiasis with brain 
abscess 
Portal vein thrombosis, pyelophlebitis, 
cardiac arrest during attempted 2nd 
transplant 
Brain injury after falling from bed, ina-
nition, and pneumonia 
----------- - ----- -------------------.-- -----------
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Fig. 1. Actuarial survival of 24 patients with primary liver 
malignancy treated by total hepatectomy and transplant 
(open circle with solid line), and of 15 patients excluding 
operative deaths (closed circle with solid line) in compari-
son to the survival of 30 patients with primary liver 
malignancy treated by subtotal hepatectomy (closed cir-
cle with broken line). 
The timing and location of the recurrences in 
these 10 patients are shown in Table 3. V sually , 
metastases were evident within a few months. The 
most commonly involved organ was the liver homo-
graft (7 patients), followed by the lung and brain (3 
patients each). Recurrences were seen with all of 
the tumor types. "Cures" were obtained only with 
hepatoma and hepatoblastoma, but long survival 
with known metastases was seen after treatment of 
bile duct carcinoma and a sarcoma. 
Two of the 3 patients who did not develop 
metastases died after 3 and 6 months, respectively. 
Their follow-ups may have been too short for 
microscopic recurrences to become evident. The 
third patient is living after 10 months (Table 3). 
The 9 patients who died from early postoperative 
complications within a month accounted for an 
overall operative mortality of 37.5%. One of these 
patients was from Group I and the other 8 from 
Group II. The 2 remaining patients from Group I are 
still alive after 3 and 11 years. 
The 7 patients who died from metastases were all 
in Group III. Long survival (maximum, 52 months) 
was sporadically seen even after recurrence was 
first known. 
The only patients thought to be definitely free of 
tumor are the 2 long survivors of Group I who had 
incidental tumors. It is as yet too early (10 months 
post-transplantation) for more than a hopeful prog-
nosis in 1 Group III patient who had a hepatoma. 
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Actuarial survival curves were constructed of the 
total group of 24 recipients and of 15 patients who 
survived more than 1 month after transplantation 
(Fig. 1). Excluding the early deaths. the 15 who 
survived had 1-, 2-, and 3-year survival of 53%, 
38%, and 29%, respectively. 
Discussion 
These results were compared to those of 30 patients 
with primary liver malignancy treated with subtotal 
hepatectomy (20 had right trisegmentectomy) dur-
ing the same period. The I-month mortality was 
6.7% in the subtotal hepatectomy group, and the 
survival (uncorrected for operative mortality as was 
done in the transplant series) was 77%, 56%, and 
52% at 1. 2 and 3 years, respectively (Fig. 1). 
Thus, the salvage in the transplantation series 
was distinctly inferior to that in patients who had 
conventional subtotal hepatic resection, and the 
only definite cures were in the 2 patients with 
incidental hepatic malignancies. A third patient has 
had quiescent tumor for more than 4 years. 
Nevertheless, an unduly pessimistic attitude 
about transplantation for malignancy is not fully 
warranted. A significant, although small. salvage 
was possible in those recipients who survived oper-
ation despite advanced stages of malignancy usually 
present. This was particularly striking in the hand-
ful of patients who lived for meaningful periods in 
spite of eventually lethal recurrences. Most of their 
postoperative lives were spent outside the hospital. 
Caine and Williams have maintained an optimis-
tic attitude for primary hepatic malignancy [4]. 
Their position is defensible, provided there is ex-
tremely discriminating case selection. To us there is 
no strong reason at present to consider any of the 
categories of liver tumors to be either especially 
advantageous or disadvantageous in the consider-
ation of candidacy. A persuasive case can be made 
for treating intrahepatic duct cell carcinomas 
(Klatskin tumors) with alternative palliative tech-
niques such as V-tube drainage and radiation [5]. 
Resume 
La recidive tumorale aprcs transplantation hepa-
tique pour cancer du foie est frequente cependant 
ce mode de traitement est susceptible d'entrainer 
une amelioration de l'etat du malade meme s'il 
meurt de recidive. Deux malades qui ont subi une 
transplantation hepatique sont apparemment 
gueris. Il sera possible d'ameliorer les resultats de 
la transplantation hepatique pour tumeur maligne 
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primitive du foie en selectionnant les cas a operer 
avec precision. 
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